Literature DB >> 26136504

Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.

Yongmin Yan1, Xiangsheng Zuo1, Daoyan Wei2.   

Abstract

UNLABELLED: The reception and integration of the plethora of signals a cell receives from its microenvironment determines the cell's fate. CD44 functions as a receptor for hyaluronan and many other extracellular matrix components, as well as a cofactor for growth factors and cytokines, and thus, CD44 is a signaling platform that integrates cellular microenvironmental cues with growth factor and cytokine signals and transduces signals to membrane-associated cytoskeletal proteins or to the nucleus to regulate a variety of gene expression levels related to cell-matrix adhesion, cell migration, proliferation, differentiation, and survival. Accumulating evidence indicates that CD44, especially CD44v isoforms, are cancer stem cell (CSC) markers and critical players in regulating the properties of CSCs, including self-renewal, tumor initiation, metastasis, and chemoradioresistance. Furthermore, there is ample evidence that CD44, especially CD44v isoforms, are valuable prognostic markers in various types of tumors. Therefore, therapies that target CD44 may destroy the CSC population, and this holds great promise for the cure of life-threatening cancers. However, many challenges remain to determining how best to use CD44 as a biomarker and therapeutic target. Here we summarize the current findings concerning the critical role of CD44/CD44v in the regulation of cancer stemness and the research status of CD44/CD44v as biomarkers and therapeutic targets in cancer. We also discuss the current challenges and future directions that may lead to the best use of CD44/CD44v for clinical applications. SIGNIFICANCE: Mounting evidence indicates that cancer stem cells (CSCs) are mainly responsible for cancer aggressiveness, drug resistance, and tumor relapse. CD44, especially CD44v isoforms, have been identified as CSC surface markers for isolating and enriching CSCs in different types of cancers. The current findings concerning the critical role of CD44/CD44v in regulation of cancer stemness and the research status of CD44/CD44v as biomarkers and therapeutic targets in cancer are summarized. The current challenges and future directions that may lead to best use of CD44/CD44v for clinical applications are also discussed. ©AlphaMed Press.

Entities:  

Keywords:  Biomarker; CD44; Cancer stem cell; Splicing variants; Therapeutic target; Tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 26136504      PMCID: PMC4542874          DOI: 10.5966/sctm.2015-0048

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  116 in total

Review 1.  Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.

Authors:  Mayumi Tamada; Makoto Suematsu; Hideyuki Saya
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

Review 2.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links.

Authors:  Christina Scheel; Robert A Weinberg
Journal:  Semin Cancer Biol       Date:  2012-04-23       Impact factor: 15.707

3.  Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.

Authors:  Lilly Y W Bourguignon; Gabriel Wong; Christine Earle; Liqun Chen
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

4.  Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.

Authors:  Meihua Yu; Siddharth Jambhrunkar; Peter Thorn; Jiezhong Chen; Wenyi Gu; Chengzhong Yu
Journal:  Nanoscale       Date:  2012-10-18       Impact factor: 7.790

5.  Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFβ1-targeting peptides P17 and P144.

Authors:  Idoia G Zubeldia; Anne-Marie Bleau; Miriam Redrado; Diego Serrano; Alice Agliano; Carmen Gil-Puig; Fernando Vidal-Vanaclocha; Jon Lecanda; Alfonso Calvo
Journal:  Exp Cell Res       Date:  2012-11-12       Impact factor: 3.905

6.  xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.

Authors:  Momoko Yoshikawa; Kenji Tsuchihashi; Takatsugu Ishimoto; Toshifumi Yae; Takeshi Motohara; Eiji Sugihara; Nobuyuki Onishi; Takashi Masuko; Kunio Yoshizawa; Shuichi Kawashiri; Makio Mukai; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Hideyuki Saya; Osamu Nagano
Journal:  Cancer Res       Date:  2013-01-14       Impact factor: 12.701

Review 7.  CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches.

Authors:  Karin Williams; Karan Motiani; Premkumar Vummidi Giridhar; Susan Kasper
Journal:  Exp Biol Med (Maywood)       Date:  2013-03

8.  Internalization of Met requires the co-receptor CD44v6 and its link to ERM proteins.

Authors:  Susanne Hasenauer; Dieter Malinger; David Koschut; Giuseppina Pace; Alexandra Matzke; Anja von Au; Véronique Orian-Rousseau
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression.

Authors:  Balázs Bánky; Lívia Rásó-Barnett; Tamás Barbai; József Tímár; Péter Becságh; Erzsébet Rásó
Journal:  Mol Cancer       Date:  2012-11-14       Impact factor: 27.401

10.  WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells.

Authors:  Wen Jiang; David K Crossman; Elizabeth H Mitchell; Philip Sohn; Michael R Crowley; Rosa Serra
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more
  200 in total

1.  Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors.

Authors:  Jiaojiao Lan; Bing Huang; Ruixue Liu; Xinxin Ju; Yang Zhou; Jinfang Jiang; Weihua Liang; Yaoyuan Shen; Feng Li; Lijuan Pang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  4,6,4'-trimethylangelicin shows high anti-proliferative activity on DU145 cells under both UVA and blue light.

Authors:  G Miolo; G Sturaro; G Cigolini; L Menilli; A Tasso; I Zago; M T Conconi
Journal:  Cell Prolif       Date:  2018-01-10       Impact factor: 6.831

3.  Biophysical Regulation of Cancer Stem/Initiating Cells: Implications for Disease Mechanisms and Translation.

Authors:  Joseph Chen; Sanjay Kumar
Journal:  Curr Opin Biomed Eng       Date:  2017-05-19

Review 4.  APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis.

Authors:  Morgan S Schrock; Benjamin R Stromberg; Luke Scarberry; Matthew K Summers
Journal:  Semin Cancer Biol       Date:  2020-03-09       Impact factor: 15.707

5.  GL-9 peptide regulates gene expression of CD44 cancer marker and pro-inflammatory cytokine TNF-α in human lung epithelial adenocarcinoma cell line (A549).

Authors:  Kosar Hooshmand; Ahmad Asoodeh; Fatemeh Behnam-Rassouli
Journal:  Mol Cell Biochem       Date:  2016-10-04       Impact factor: 3.396

6.  PPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice.

Authors:  Xiangsheng Zuo; Yasunori Deguchi; Weiguo Xu; Yi Liu; Haiyan S Li; Daoyan Wei; Rui Tian; Weidong Chen; Min Xu; Yaying Yang; Shen Gao; Jonathan C Jaoude; Fuyao Liu; Sarah P Chrieki; Micheline J Moussalli; Mihai Gagea; Manu M Sebastian; Xiaofeng Zheng; Dongfeng Tan; Russell Broaddus; Jing Wang; Nadim J Ajami; Alton G Swennes; Stephanie S Watowich; Imad Shureiqi
Journal:  Gastroenterology       Date:  2019-03-15       Impact factor: 22.682

7.  MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.

Authors:  Jingjing Li; Tianjie Pu; Lijuan Yin; Qinlong Li; Chun-Peng Liao; Boyang Jason Wu
Journal:  Oncogene       Date:  2020-02-17       Impact factor: 9.867

8.  miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.

Authors:  Yulei Wei; Hong Li; Quanxin Qu
Journal:  Breast Cancer       Date:  2020-08-31       Impact factor: 4.239

Review 9.  Carcinoma Cell Hyaluronan as a "Portable" Cancerized Prometastatic Microenvironment.

Authors:  Eva A Turley; David K Wood; James B McCarthy
Journal:  Cancer Res       Date:  2016-04-20       Impact factor: 12.701

Review 10.  Role of Pericellular Matrix in the Regulation of Cancer Stemness.

Authors:  Sofia Avnet; Margherita Cortini
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.